Company Overview of Protein Sciences Corporation
Protein Sciences Corporation develops, manufactures, and commercializes vaccines and biopharmaceuticals for the prevention and treatment of various diseases. The company offers Flublok, a recombinant protein-based seasonal influenza vaccine; Panblok, a pandemic influenza vaccine; FluNhance that is used to enhance additive to influenza vaccines; and SARS (D3252), a Severe Acute Respiratory Syndrome vaccine that is used to elicit neutralizing antibodies to the virus. It also provides Baculovirus Expression Vector System, a platform technology used for the development of a range of vaccines and therapeutics, such as prophylactic vaccines, therapeutic vaccines, gene therapy, and biologic applica...
1000 Research Parkway
Meriden, CT 06450
Founded in 1983
Key Executives for Protein Sciences Corporation
Chief Executive Officer, President and Director
Chief Administrative Officer, Senior Vice President and Corporate Secretary
Senior Vice President of Manufacturing Operations
Senior Vice President of Quality
Compensation as of Fiscal Year 2016.
Protein Sciences Corporation Key Developments
Protein Sciences Corporation Announces Release of First Lots of Flublok® Influenza Vaccine
Aug 10 16
Protein Sciences Corporation announced that the FDA has approved and released the first lots of Flublok® influenza vaccine for distribution this season. Doses have been shipped and healthcare professionals and pharmacies that have pre-ordered Flublok should receive the vaccine this week. Flublok is approved for all people 18 and older and was recently shown in a clinical study of adults 50 and older to provide over 40% better protection against cell culture confirmed influenza compared to a flu vaccine made using embryonated hens' eggs the 60 – year old vaccine production technology. Flublok also offers a pure choice for vaccination as it is comprised of purified protein and lacks the unnecessary ingredients contained in other flu vaccines, such as influenza virus, antibiotics, preservatives, egg protein, gelatin or latex.
Protein Sciences Corporation Gets FDA Approval for 2016/17 Formulation of Flublok Influenza Vaccine
Jul 12 16
Protein Sciences Corporation announced that FDA has approved the 2016/17 formulation of Flublok influenza vaccine. Unlike other vaccines, all flu vaccines are adjusted annually to protect against the new strains of influenza that are predicted to be the dominant circulating strains during the upcoming fall and winter. This year FDA mandated two new components be made for trivalent flu vaccines, including a new H3N2 component that is also required for quadrivalent vaccines. H3N2 vaccine components are historically the most challenging for egg-based flu vaccine manufacturers to make and are the components that have been linked to poor vaccine efficacy in the past. In contrast, Protein Sciences' technology platform for making Flublok allows for a perfect match to H3N2 strains. In a post-marketing clinical study of 9,000 adults 50 years and older during the 2014/15 flu season where H3N2 influenza was dominant, people who received Flublok were over 40% less likely to get cell culture confirmed influenza than people who received an egg-based flu vaccine. FDA approval of the 2016/17 formulation of Flublok means that Flublok is on track to ship to healthcare providers in early August.
UMN Pharma Inc. Joins Protein Sciences' International Zika Vaccine Consortium
Jun 29 16
Protein Sciences Corporation and UMN Pharma Inc. announced that UMN has signed on as the partner of the international Zika vaccine consortium initiated by Protein Sciences. The consortium, which also includes partners Sinergium Biotech (Buenos Aires, Argentina) and Mundo Sano, a private foundation with activities in Argentina, Spain and Africa, is developing a vaccine to combat the Zika virus based on Protein Sciences' proprietary technology. The partners are pooling resources to drive advancement of their vaccine candidate into the clinic as quickly as possible, which is anticipated for later this year. Under the terms of the agreement, UMN will pay an upfront fee to fund the development and manufacture of the vaccine being produced at Protein Sciences. In return, UMN will receive manufacturing and commercial rights to the vaccine in Japan and other counties to be determined.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|